News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
191,578 Results
Type
Article (18449)
Company Profile (12)
Press Release (173115)
Multimedia
Podcasts (43)
Webinars (12)
Section
Business (59072)
Career Advice (396)
Deals (8810)
Drug Delivery (85)
Drug Development (31109)
Employer Resources (41)
FDA (5028)
Job Trends (4626)
News (95251)
Policy (8546)
Tag
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Standard (2)
Academia (1065)
Accelerated approval (33)
ADA (11)
Adcomms (20)
Allergies (96)
Alliances (12672)
ALS (107)
Alzheimer's disease (1397)
Antibody-drug conjugate (ADC) (295)
Approvals (5135)
Artificial intelligence (393)
ASCO (193)
Autoimmune disease (178)
Automation (20)
Bankruptcy (63)
Best Places to Work (3707)
BIO (26)
Biologics (1)
BIOSECURE Act (8)
Biosimilars (79)
BioSpace Insights (66)
Biotechnology (6)
Bladder cancer (116)
Brain cancer (37)
Breast cancer (514)
Cancer (3611)
Cardiovascular disease (255)
Career advice (358)
Career pathing (28)
CAR-T (196)
CDC (26)
CDMO (82)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (38)
Clinical research (27969)
Collaboration (985)
Commercialization (7)
Company closure (4)
Compensation (160)
Complete response letters (46)
COVID-19 (1449)
CRISPR (49)
C-suite (748)
Cystic fibrosis (74)
Data (4524)
Decentralized trials (1)
Denatured (8)
Depression (90)
Dermatology (58)
Diabetes (261)
Diagnostics (3355)
Digital health (25)
Diversity (4)
Diversity, equity & inclusion (13)
Drug discovery (189)
Drug pricing (109)
Drug shortages (16)
Duchenne muscular dystrophy (158)
Earnings (23364)
Editorial (50)
Employer branding (5)
Employer resources (43)
Events (22893)
Executive appointments (553)
FDA (6840)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (18)
Frontotemporal dementia (21)
Funding (889)
Gene editing (128)
Generative AI (37)
Gene therapy (431)
GLP-1 (555)
Government (1673)
Grass and pollen (3)
Guidances (186)
Healthcare (5350)
Hematology (81)
HIV (48)
Huntington's disease (42)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (66)
Immunology and inflammation (208)
Immuno-oncology (73)
Indications (104)
Infectious disease (1619)
Inflammatory bowel disease (74)
Inflation Reduction Act (6)
Influenza (57)
Intellectual property (126)
Interviews (85)
IPO (4286)
IRA (23)
Job creations (1047)
Job search strategy (263)
JPM (39)
Kidney cancer (18)
Labor market (48)
Layoffs (297)
Leadership (20)
Legal (1454)
Licensing (7)
Liver cancer (44)
Longevity (11)
Lung cancer (508)
Lymphoma (289)
Machine learning (43)
Management (16)
Manufacturing (489)
Marketing (4)
MASH (110)
Medical affairs (1)
Medical device (3432)
Medtech (3515)
Mergers & acquisitions (4952)
Metabolic disorders (774)
mRNA (137)
Multiple sclerosis (111)
NASH (13)
Neurodegenerative disease (326)
Neuropsychiatric disorders (69)
Neuroscience (2292)
Neurotech (1)
NextGen: Class of 2026 (1620)
Non-profit (1415)
Now hiring (8)
Obesity (405)
Opinion (201)
Ovarian cancer (117)
Pain (94)
Pancreatic cancer (208)
Parkinson's disease (238)
Partnered (18)
Patents (207)
Patient recruitment (389)
Peanut (30)
People (17422)
Pharmaceutical (3)
Pharmacy benefit managers (12)
Phase 1 (8835)
Phase 2 (12446)
Phase 3 (9841)
Pipeline (5526)
Policy (162)
Postmarket research (711)
Preclinical (2929)
Press Release (28)
Prostate cancer (193)
Psychedelics (40)
Radiopharmaceuticals (156)
Rare diseases (678)
Real estate (1433)
Recruiting (16)
Regulatory (8083)
Reports (20)
Research institute (1034)
Resumes & cover letters (44)
Rett syndrome (33)
RNA editing (19)
RSV (50)
Schizophrenia (96)
Series A (158)
Series B (110)
Service/supplier (1)
Sickle cell disease (58)
Special edition (11)
Spinal muscular atrophy (104)
Sponsored (22)
Startups (1530)
Stomach cancer (10)
Supply chain (36)
Tariffs (60)
The Weekly (34)
Vaccines (558)
Venture capital (100)
Weight loss (295)
Women's health (63)
Worklife (9)
Date
Last 7 days (174)
Last 30 days (980)
Last 365 days (12189)
2026 (8238)
2025 (11424)
2024 (11897)
2023 (13196)
2022 (16098)
2021 (16892)
2020 (15865)
2019 (12180)
2018 (9471)
2017 (9517)
2016 (8514)
2015 (9586)
2014 (6452)
2013 (4774)
2012 (5213)
2011 (5504)
2010 (4806)
Location
Africa (223)
Alabama (28)
Alaska (1)
Arizona (87)
Arkansas (4)
Asia (12016)
Australia (2397)
California (5421)
Canada (1317)
China (706)
Colorado (194)
Connecticut (224)
Delaware (181)
Europe (29570)
Florida (722)
Georgia (142)
Hawaii (1)
Idaho (8)
Illinois (394)
India (46)
Indiana (226)
Iowa (7)
Japan (284)
Kansas (47)
Kentucky (12)
Louisiana (16)
Maine (18)
Maryland (537)
Massachusetts (4049)
Michigan (100)
Minnesota (193)
Mississippi (2)
Missouri (50)
Montana (7)
Nebraska (10)
Nevada (61)
New Hampshire (42)
New Jersey (1440)
New Mexico (16)
New York (1523)
North Carolina (511)
Northern California (2805)
Ohio (114)
Oklahoma (12)
Oregon (13)
Pennsylvania (892)
Puerto Rico (10)
Rhode Island (12)
South America (245)
South Carolina (16)
Southern California (2197)
Tennessee (65)
Texas (1053)
United States (18555)
Utah (181)
Virginia (102)
Washington D.C. (27)
Washington State (418)
West Virginia (1)
Wisconsin (62)
191,578 Results for "earli".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IN PARTNERSHIP WITH ARVINAS
Life after the lead asset: Advancing an early-stage pipeline
In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away.
July 30, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Lung cancer
Summit shares descend as PD-1/VEGF asset misses early survival mark
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
May 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Anchored in the 2026 global campaign’s core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no patient is left behind.
July 31, 2026
·
4 min read
Opinion
The FDA must put biotech at its center or continue to cede early research to China
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.
July 6, 2026
·
4 min read
·
Kendalle Burlin O’Connell
Insights
Biotech angels lean into deeper diligence and disciplined early bets
Angel investors are raising the bar with tighter criteria, backing strong teams, realistic markets and clear paths to exit while applying deeper, domain-specific diligence to early stage bets.
April 29, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Approvals
RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
The FDA granted the approval of Revolution Medicines’ daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.
August 26, 2026
·
2 min read
·
Annalee Armstrong
Obesity
Enveda’s exercise-simulating obesity tablet clears early clinical test
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
August 19, 2026
·
2 min read
·
Nick Paul Taylor
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
April 24, 2026
·
2 min read
·
Tristan Manalac
IPO
Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
August 20, 2026
·
3 min read
·
Gabrielle Masson
Pipeline
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’
Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.
August 24, 2026
·
1 min read
·
Tristan Manalac
1 of 19,158
Next
